I-Mab (NASDAQ:IMAB) ADRs traded ~11% higher in the premarket after the biotech indicated a faster-than-expected advancement in its Phase 1b trial for its experimental gastric cancer therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback